Building on Success: BMC2 Leadership Transition

BMC2 is under new leadership beginning October 1, 2025. Dr. Nicholas Osborne is the new BMC2 Program Director. Dr. Eric Cantey is the new Director of BMC2 PCI. Dr. Osborne has short brown hair and smiling, wearing blue-rimmed glasses, a dark jacket, light collared shirt, and tie. Dr. Cantey has short dark hair, glasses, and is smiling, wearing a white coat and yellow tie.
|
Elizabeth Horn

BMC2 will be under new leadership beginning October 1, 2025.

Dr. Nicholas Osborne, Director of BMC2 Vascular Surgery, will assume the role of Director of BMC2 on October 1, 2025.

Dr. Eric Cantey, who joined BMC2 as Associate Director of BMC2 PCI this year, will become Director of BMC2 PCI.

Dr. Hitinder Gurm who has served as Director of BMC2 and its Percutaneous Coronary Intervention (PCI) registry since 2008 will step down and transition to a strategic role as Chair of a new BMC2 Executive Board, forming later in 2025.

New Leaders

Dr. Osborne is a vascular surgeon who also has expertise in complex statistical methods and using large databases to examine variation in quality of care in the United States. He has long focused on examining physician and patient decision-making and determining the real-world long-term outcomes of treatment of Peripheral Artery disease.

“I am excited to build upon the successes BMC2-participating hospitals and centers have seen under Dr. Gurm’s guidance and expertise as director,” Dr. Osborne said. “He is the ultimate champion for patients, and I strive to lead BMC2 with the same passion and dedication.”

Dr. Cantey's research interests include quality improvement in PCI and comparative effectiveness of cardiovascular therapies. He leads BMC2’s efforts to develop a statewide protocol to improve care for patients with cardiogenic shock.

Dr. Nicholas Osborne will become the new BMC2 Program Director on October 1. Dr. Eric Cantey will become Director of BMC2 PCI. A new Executive Board will form later in 2025.

BMC2’s Transition Plan 

The Consortium will implement a new Executive Board with Dr. Gurm serving as the inaugural Chair.

The Executive Board Chair of BMC2 will provide strategic leadership and governance oversight to support the Consortium’s growth and impact in cardiovascular care across Michigan.

The Board will bring together a comprehensive team of experts to ensure the collaborative's success. Dr. Gurm will guide strategic direction and tactics that strengthen our partnership with Blue Cross Blue Shield of Michigan, influence policy, and elevate BMC2’s profile nationally and globally.

“I have been honored to serve Michigan’s cardiovascular patients and their families throughout my tenure as Program Director,” he said. “Drs. Osborne and Cantey, the BMC2 team, and our colleagues around the state are exceptional partners in this work; their commitment to improving quality of care and outcomes is unmatched and I am grateful for their guidance and support over the years.”

About Dr. Osborne

Dr. Osborne is the Director of BMC2 Vascular Surgery. He is an Associate Professor of Surgery and Associate Program Director for the Michigan Medicine Vascular Surgery residency and fellowship training programs. Dr. Osborne practices at both the Frankel Cardiovascular Center and the Ann Arbor Veteran's Affairs Hospital. He is the Chief of Surgery at the LTC Charles S Kettles VA Medical Center, Ann Arbor.  His clinical interests include peripheral artery disease, cerebrovascular disease, complex endovascular surgery, and aortic disease. He is a member of the Institute for Healthcare Policy and Innovation. Dr. Osborne has expertise in complex statistical methods and using large databases to examine variation in the care and the quality of care in the United States. He has received both an American Heart Association Career Development Award and an NIH K08 award. His primary focus has been to examine physician and patient decision-making and determine the real-world long-term outcomes of Medical, Endovascular and Surgical treatment of PAD. Dr. Osborne has published in high-profile journals including, the New England Journal of Medicine, JAMA, Journal of the American Heart Association, Journal of Vascular Surgery, and Medical Care.  Nationally, he is chair of the Appropriateness Committee of the Society for Vascular Surgery, and he is a member of the Executive Council for the Vascular Quality Initiative.

About Dr. Cantey

Dr. Eric Cantey is the Associate Director of BMC2 PCI. He is an Assistant Clinical Professor in the Department of Medicine and an interventional cardiologist at Michigan Medicine. Dr. Cantey graduated AOA from Tufts University School of Medicine. He completed his residency in Internal Medicine at Northwestern University in Chicago, Illinois, where he served as a Chief Resident. He then continued his training at Northwestern by completing fellowships in general cardiology, interventional cardiology, and advanced structural and complex coronary disease fellowships. During his fellowship, he obtained a Master of Science in Clinical Investigation.  Dr. Cantey's research interests include quality improvement in PCI and comparative effectiveness of cardiovascular therapies, particularly for complex coronary disease and cardiogenic shock.

About Dr. Gurm

Dr. Hitinder S. Gurm is a Professor of Internal Medicine and the Chief Medical Officer for U-M Health. Dr. Gurm is a graduate of Christian Medical College, Ludhiana, India. He did his residency in Internal medicine followed by a fellowship in Cardiology and Interventional Cardiology at the Cleveland Clinic Foundation. His research interests include carotid interventions, contrast-induced nephropathy, quality improvement and outcomes assessment, and development of novel devices for endovascular interventions. He has published more than 250 original articles and book chapters and has been named as an inventor on 4 patents. He is the recipient of the Michigan Health & Hospital Association’s Patient Safety & Quality Leadership Award for 2016 and has been elected to the American Society for Clinical Investigation (ASCI). Dr. Gurm was selected as one of 50 experts leading the field of patient safety in 2018 by Becker Hospital Review.

About BMC2

BMC2 is one of 22 Collaborative Quality Initiatives (CQIs) sponsored by Blue Cross Blue Shield. CQIs work to improve many of the most common and costly areas of surgical and medical care in Michigan.

BMC2 comprises three multi-center quality improvement registries:

  • Percutaneous Coronary Intervention (PCI); procedures that treat blockages in the arteries that supply blood to the heart, including heart stenting.
  • Vascular Surgery - conditions related to blood vessels including:
  • Peripheral Vascular Disease - Issues with blood flow in the arms, legs, and other parts of the body.
  • Aneurysms - Weakened areas in blood vessels that can bulge or even burst.
  • Carotid Arteries - The main arteries that carry blood to the brain and head.
  • The Michigan Structural Heart Consortium (MISHC) – a collaboration between BMC2 and the Michigan Society of Thoracic and Cardiovascular Surgeons (MSTCVS) – serves patients who undergo structural heart procedures including transcatheter aortic valve replacement, mitral valve replacement, and mitral valve repair procedures.

The collaborative also includes the Michigan Cardiac Rehab Network, a collaboration with fellow CQIs, the Michigan Value Collaborative (MVC) and the Michigan Society of Thoracic and Cardiovascular Surgeons (MSTCVS).

In 2024, the State of Michigan recognized BMC2’s “innovative spirit and unwavering dedication” as a pioneer in cardiovascular care in a special tribute and BMC2 received the prestigious 2023 John M. Eisenberg Patient Safety and Quality Award in the Local Level Innovation in Patient Safety and Quality category.